Insiders Travere Therapeutics, Inc.

Equities

Real-time Estimate Cboe BZX Other stock markets 03:21:31 2024-05-15 pm EDT			5-day change	1st Jan Change
6.85 ^USD	+2.24%		+0.51%	-23.75%

May. 07	Canaccord Genuity Adjusts Price Target on Travere Therapeutics to $18 From $15, Maintains Buy Rating	MT
May. 06	Travere Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

AnaptysBio Names John Orwin as Board Chairman	23-09-18	MT
Insider Sell: Travere Therapeutics	23-01-26	MT
Insider Sell: Travere Therapeutics	23-01-06	MT
Travere Therapeutics Names Chris Cline CFO	22-04-20	MT
Insider Sell: Travere Therapeutics	22-01-12	MT
Insider Sell: Travere Therapeutics	22-01-12	MT
Travere Therapeutics, Inc. Announces Executive Changes	22-01-06	CI
Travere Therapeutics Names Jula Inrig Chief Medical Officer	22-01-04	MT
Travere Therapeutics, Inc. Appoints Jula Inrig, M.D., as Chief Medical Officer	22-01-04	CI
Insider Sell: Travere Therapeutics	21-11-09	MT
Insider Sell: Travere Therapeutics	21-11-03	MT
Travere Therapeutics : Chief Medical Officer to Shift to Adviser Role at Yearend	21-10-12	MT
Travere Therapeutics, Inc. Announces Executive Changes	21-10-12	CI
Insider Sell: Travere Therapeutics	21-10-08	MT
Travere Therapeutics, Inc. Announces Management Changes	21-09-17	CI
Travere Therapeutics : Appoints Kaiser Foundation Executive Ruth Williams-Brinkley to Board	21-09-14	MT
Travere Therapeutics, Inc. Appoints Ruth Williams-Brinkley to its Board of Directors	21-09-14	CI
Insider Trends: Insider Extends 90-Day Selling Trend at Travere Therapeutics	21-06-03	MT
Insider Trends: Travere Therapeutics Insider Sale Scales Back 90-Days of Buys	21-02-09	MT
Insider Trends: 90-Days of Insider Buying at Travere Therapeutics Interrupted with Share Sale	21-02-09	MT

No results for this search